Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 5/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24215695 | 0.86 | ADORA2A (0.37) | JAK1JAK2JAK3DRD2MAP3K12 | |
| SCHEMBL30412721 | 0.86 | ADORA2A (0.37) | JAK1JAK2JAK3DRD2MAP3K12 | |
| SCHEMBL23623623 | 0.85 | JAK2 (0.40) | JAK1JAK2TYK2JAK3DCPS | |
| SCHEMBL23623010 | 0.85 | DRD2 (0.42) | JAK1JAK2TYK2JAK3DCPS | |
| SCHEMBL23612018 | 0.79 | DRD2 (0.41) | JAK1JAK2TYK2JAK3DCPS | |
| SCHEMBL3371065 | 0.79 | GRM4 (0.32) | — | |
| SCHEMBL24215216 | 0.75 | KDM1A (0.39) | JAK1JAK2TYK2JAK3MAPK14 | |
| SCHEMBL23622940 | 0.75 | SCN10A (0.39) | MAPK14PIK3CAPIK3CBDRD2 | |
| SCHEMBL23623011 | 0.74 | MAPK14 (0.42) | JAK1JAK2TYK2JAK3MAPK14 | |
| SCHEMBL25386216 | 0.74 | OPRL1 (0.36) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| WO-2022015957-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2021138434-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | JAK1 393/4885JAK2 501/4885TYK2 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.